Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298661 | 0.81 | KMT2A (0.37) | ALDH1A1GAAMAPTMAPK1GRIN1 | |
| SCHEMBL660685 | 0.79 | ALDH1A1 (0.40) | ALDH1A1GAAMAPTMAPK1GRIN1 | |
| SCHEMBL661279 | 0.77 | HPGD (0.37) | ALDH1A1MAPTMAPK1KDM4EHTT | |
| SCHEMBL297726 | 0.74 | MAPT (0.38) | ALDH1A1MAPTMAPK1GRIN1GRIN2B | |
| SCHEMBL297066 | 0.69 | SMN1; SMN2 (0.37) | ALDH1A1GAAMAPTMAPK1GRIN1 | |
| SCHEMBL287429 | 0.67 | NPSR1 (0.36) | ALDH1A1GAAMAPTMAPK1GRIN1 | |
| SCHEMBL7808911 | 0.66 | ALDH1A1 (0.48) | ALDH1A1MAPTMAPK1KDM4ECASP1 | |
| SCHEMBL659986 | 0.66 | NPC1 (0.35) | ALDH1A1MAPTMAPK1GRIN1GRIN2B | |
| SCHEMBL287279 | 0.66 | GRM5 (0.39) | ALDH1A1GAAMAPTMAPK1KDM4E | |
| SCHEMBL661697 | 0.66 | DAO (0.35) | ALDH1A1GAAMAPTMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | ALDH1A1 676/4885GAA 194/4885MAPT 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.